UTHR stock rises 12.5% on promising data from TETON-1 Tyvaso study

Shares of United Therapeutics UTHR rallied 12.5% on Monday after the company unveiled robust data from the phase III TETON-1 study evaluating nebulized Tyvaso for the treatment of patients with idiopathic pulmonary fibrosis (IPF), a devastating lung disease with limited treatment options. UTHR’s TETON program comprises two late-stage parallel studies—TETON-1 conducted in the United States and Canada, and TETON-2 internationally—with top-line...